Ambrosia Biosciences, a Boulder, CO-based drug discovery company, raised $25M in Series A funding.
The round was led by Merck with participation from participation from existing investors BVF Partners and Boulder Ventures.
The company intends to use the funds to expand its preclinical development operations.
Led by Nick Traggis, Founder and CEO, Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
FinSMEs
11/12/2024